Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial (Mar, 10.1038/s41591-026-04315-8, 2026)

Authors
Category Primary study
JournalNATURE MEDICINE
Year 2026
This article has no abstract
Epistemonikos ID: 409caac1526c2914100c5de5187ba363c95d1981
First added on: May 06, 2026